Organigram & Village Farms Earnings Breakdown
Trade to Black welcomes two Canadian LP chief executives for a CEO-focused episode. In our latest Trade To Black podcast presented by Flowhub, hosts Shadd Dales and Anthony Varrell touch base with two major CEOs in the cannabis space following another busy week of earnings season. First up, Organigram Holdings Inc (NASDAQ:OGI) CEO James Yamanaka joins the show after a softer quarterly earnings report that left questions by investors. Then in segment two, Village Farms International Inc. (NASDAQ:VFF) CEO Michael DeGiglio returns to the podcast following another strong earnings report, including 171% year-over-year international cannabis growth.
Organigram CEO James Yamanaka, four months into the role, addresses a disappointing fiscal Q2 earnings print of $59.8 million. There was a lot of respect for the transparency James brought to the conversation, openly explaining some of the operational issues tied to vapes and infused pre-rolls, while also outlining why he still believes the long-term story remains intact. After multiple acquisitions and major expansion moves over the last 18 months, James explains why management believes these are fixable operational issues rather than deeper problems inside the business.
On the international front, he reports the Sanity Group acquisition in Germany is tracking well, with April results putting the company on pace to hit its stated target of 25 million euros per quarter. He also highlighted a recreational pilot underway in Switzerland and signaled Organigram will pursue further market expansion prudently, prioritizing only markets where it believes it can finish in the top three.
Village Farms CEO Michael DeGiglio joins the show to discuss what he describes as a statement quarter rather than just a strong one, highlighted by 171 percent year-over-year international revenue growth. DeGiglio credited decades of greenhouse cultivation expertise and a six-year commitment to EU GMP certification as the foundation of the company’s competitive moat, pushing back on the notion that U.S. operators will easily dominate global export markets once rescheduling fully takes hold. He argues that stability testing, regulatory compliance on both sides of the Atlantic, and the learning curve required to achieve genuine pharmaceutical-grade standards represent significant barriers that take years, not months, to clear.
On the U.S. opportunity, DeGiglio confirmed the company is actively re-evaluating its Texas assets and broader American entry strategy in light of the rescheduling announcement, framing the April order as a transformational moment for the global industry.
